The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cognitive Function in a Randomized Trial of Evolocumab
Open accessAbstract
Background Findings from clinical trials of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits. Methods In a subgroup of patients from a randomized, placebo-controlled trial of evolocumab added to statin therapy, we prospectively assessed cognitive function using the Cambridge Neuropsychological Test Automated Battery. The primary end point was the score on the spatial working memory strategy index of executive function (scores range from 4 to 28, with lower scores indicating a more efficient use of strategy and planning). Secondary end points were the scores for working memory (scores range from 0 to 279, with lower scores indicating fewer errors), episodic memory (scores range from 0 to 70, with lower scores indicating fewer errors), and psychomotor speed (scores range from 100 to 5100 msec, with faster times representing better performance). Assessments of cognitive function were performed at baseline, week 24, yearly, and at the end of the trial. The primary analysis was a noninferiority comparison of the mean change from baseline in the score on the spatial working memory strategy index of executive function between the patients who received evolocumab and those who received placebo; the noninferiority margin was set at 20% of the standard deviation of the score in the placebo group. Results A total of 1204 patients were followed for a median of 19 months; the mean (±SD) change from baseline over time in the raw score for the spatial working memory strategy index of executive function (primary end point) was -0.21±2.62 in the evolocumab group and -0.29±2.81 in the placebo group (P<0.001 for noninferiority; P=0.85 for superiority). There were no significant between-group differences in the secondary end points of scores for working memory (change in raw score, -0.52 in the evolocumab group and -0.93 in the placebo group), episodic memory (change in raw score, -1.53 and -1.53, respectively), or psychomotor speed (change in raw score, 5.2 msec and 0.9 msec, respectively). In an exploratory analysis, there were no associations between LDL cholesterol levels and cognitive changes. Conclusions In a randomized trial involving patients who received either evolocumab or placebo in addition to statin therapy, no significant between-group difference in cognitive function was observed over a median of 19 months. (Funded by Amgen; EBBINGHAUS ClinicalTrials.gov number, NCT02207634 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Trials of PCSK9 inhibitors in cardiovascular populations consistently showed substantial reductions in LDL cholesterol without negative cognitive effects [11,22].”
From The Roles of PCSK9 in Alzheimer’s Disease: A Systematic Review of Clinical, Genetic, and Preclinical Evidence (2025) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“an anti-PCSK9 antibody study observed no significant between-group difference in cognitive function over a median of 19 months [66].”
From PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier (2022) · cites this paper as [66]
The cited source says what the claim attributes to it.
In the citing paper
“large cardiovascular trials of PCSK9 antibodies such as evolocumab have not demonstrated cognitive harm10,43”
From Small-molecule PCSK9 inhibition enhances BBB amyloid-β clearance and suppresses microglial inflammation in Alzheimer’s disease models (2026) · cites this paper as [43]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, no change in cognitive function has been reported in studies with the addition of ezetimibe (119) or PCSK9 inhibitors (121,170) to statin therapy, including among individuals treated to very low LDL cholesterol levels.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [170]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, no change in cognitive function has been reported in studies with the addition of ezetimibe (112) or PCSK9 monoclonal antibodies (115,164) to statin therapy, including among individuals treated to very low LDL cholesterol levels.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [164]
The cited source says what the claim attributes to it.
In the citing paper
“Our findings are in line with data from PCSK9 inhibitor clinical trials (Giugliano et al., 2017; Mannarino et al., 2018; Gencer et al., 2020; Ray et al., 2020) and from observations that people carrying loss-of-function mutations of the PCSK9 gene have no signs of neurological defects (Cohen et al., 2005, 2006; Zhao et al., 2006; Hooper et al., 2007; Mefford et al., 2018).”
From PCSK9 deficiency alters brain lipid composition without affecting brain development and function (2023) · cites this paper as Giugliano et al., 2017
In the citing paper
“The absolute benefit from statin treatment was lower in people in primary prevention, who are typically at lower risk [36,38,214,215].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citationEfficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Self-citationEfficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Self-citationPlanning and spatial working memory following frontal lobe lesions in man
Owen, A. M., Downes, J. J., Sahakian, B. J., Polkey, C. E., & Robbins, T. W. (1990) · Neuropsychologia · doi:10.1016/0028-3932(90)90137-d · Cited by 1,284
SAHAKIAN, B. J., MORRIS, R. G., EVENDEN, J. L., HEALD, A., LEVY, R., PHILPOT, M., & ROBBINS, T. W. (1988) · Brain · doi:10.1093/brain/111.3.695 · Cited by 666
The measurement of everyday cognition (ECog): Scale development and psychometric properties.
Farias, S. T., Mungas, D., Reed, B., Cahn, D. A., Jagust, W. J., Baynes, K., & DeCarli, C. S. (2008) · Neuropsychology · doi:10.1037/0894-4105.22.4.531 · Cited by 665
Robbins, T. W., James-Galton, M., Owen, A. M., Sahakian, B. J., Lawrence, A. D., McInnes, L., & Rabbitt, P. (1998) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617798455073 · Cited by 629
Schmermund, A., Möhlenkamp, S., Stang, A., Grönemeyer, D. H. W., Seibel, R. M. M., Hirche, H., Mann, K., Siffert, W., Lauterbach, K. W., Siegrist, J., et al. (2002) · American Heart Journal · doi:10.1067/mhj.2002.123579 · Cited by 582
Flagged first, then by citations
Research works printed but not linked: 1
- Jessup C. Cambridge Cognition awarded FDA marketing clearance for Cantab mobile. FDA News. January 26, 2017 (http://www.fdanews.com/articles/180219-cambridge-cognition-awarded-fda-marketing-clearance-for-cantab-mobile).
Cited by
Sorted by citations
Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000625 · Cited by 6,185
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
Self-citationGrundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691
Martin, S. S., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Barone Gibbs, B., Beaton, A. Z., Boehme, A. K., et al. (2024) · Circulation · doi:10.1161/cir.0000000000001209 · Cited by 2,800
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.002 · Cited by 1,751
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Martin, S. S., Aday, A. W., Allen, N. B., Almarzooq, Z., Anderson, C. A. M., Arora, P. K., Avery, C. L., Baker-Smith, C. M., Bansal, N., Beaton, A., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001303 · Cited by 1,284
Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C. T., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S. D., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000624 · Cited by 933
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s010 · Cited by 869
Giugliano, R. P., Pedersen, T. R., Park, J.-G., De Ferrari, G. M., Gaciong, Z. A., Ceska, R., Toth, K., Gouni-Berthold, I., Lopez-Miranda, J., Schiele, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32290-0 · Cited by 682
Self-citationVirani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
Duan, Y., Gong, K., Xu, S., Zhang, F., Meng, X., & Han, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01125-5 · Cited by 538
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s010 · Cited by 495
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s010 · Cited by 487
9. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2018
(2017) · Diabetes Care · doi:10.2337/dc18-s009 · Cited by 505
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s010 · Cited by 471
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Das, S. R., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s010 · Cited by 438
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy182 · Cited by 370
Self-citationPCSK9 inhibitors: clinical evidence and implementation
Sabatine, M. S. (2019) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0107-8 · Cited by 338
Self-citationDamluji, A. A., Forman, D. E., Wang, T. Y., Chikwe, J., Kunadian, V., Rich, M. W., Young, B. A., Page, R. L., II, DeVon, H. A., & Alexander, K. P. (2022) · Circulation · doi:10.1161/cir.0000000000001112 · Cited by 391
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Das, S. R., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s010 · Cited by 339
PCSK9: From Basic Science Discoveries to Clinical Trials
Shapiro, M. D., Tavori, H., & Fazio, S. (2018) · Circulation Research · doi:10.1161/circresaha.118.311227 · Cited by 285
The Evolving Future of PCSK9 Inhibitors
Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264
Wilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.004 · Cited by 239
2023 Chinese guideline for lipid management
Li, J., Zhao, S., Zhao, D. H., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1190934 · Cited by 241
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis
Semb, A. G., Ikdahl, E., Wibetoe, G., Crowson, C. S., & Rollefstad, S. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0428-y · Cited by 221
Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B. E., Camaj, A., Kalkman, D. N., Vogel, B., Sartori, S., De Rosa, S., Baber, U., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehz430 · Cited by 208
Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Borén, J., Farnier, M., Ference, B. A., Gielen, S., Graham, I., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx549 · Cited by 200
Olmastroni, E., Molari, G., De Beni, N., Colpani, O., Galimberti, F., Gazzotti, M., Zambon, A., Catapano, A. L., & Casula, M. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab208 · Cited by 197
The dawn of a new era of targeted lipid-lowering therapies
Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171
PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021
Banach, M., Burchardt, P., Chlebus, K., Dobrowolski, P., Dudek, D., Dyrbuś, K., Gąsior, M., Jankowski, P., Jozwiak, J. J., Kłosiewicz−Latoszek, L., et al. (2021) · Archives of Medical Science · doi:10.5114/aoms/141941 · Cited by 168
Vascular Cognitive Impairment and Dementia
Wong, E. C., & Chui, H. C. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001124 · Cited by 170
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia
Koren, M. J., Sabatine, M. S., Giugliano, R. P., Langslet, G., Wiviott, S. D., Ruzza, A., Ma, Y., Hamer, A. W., Wasserman, S. M., & Raal, F. J. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.1024 · Cited by 150
Self-citationInhibiting PCSK9 — biology beyond LDL control
Stoekenbroek, R. M., Lambert, G., Cariou, B., & Hovingh, G. K. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0110-5 · Cited by 141
Wilson, P. W. F., Polonsky, T. S., Miedema, M. D., Khera, A., Kosinski, A. S., & Kuvin, J. T. (2019) · Circulation · doi:10.1161/cir.0000000000000626 · Cited by 137
Makover, M. E., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100371 · Cited by 139
Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function
Rosoff, D. B., Bell, A. S., Jung, J., Wagner, J., Mavromatis, L. A., & Lohoff, F. W. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.05.041 · Cited by 126
A radioimmunoassay for bradykinin in plasma and synovial fluid.
Talamo, R. C., Haber, E., & Austen, K. F. (1969) · PubMed · Cited by 120
Inclisiran—New hope in the management of lipid disorders?
Dyrbuś, K., Gąsior, M., Penson, P., Ray, K. K., & Banach, M. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.11.001 · Cited by 120
Packard, C. J., Chapman, M. J., Sibartie, M., Laufs, U., & Masana, L. (2021) · Heart · doi:10.1136/heartjnl-2020-318760 · Cited by 114
Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults
Zhou, Z., Ryan, J. L., Ernst, M. E., Zoungas, S., Tonkin, A. M., Woods, R. L., McNeil, J. J., Reid, C. M., Curtis, A. J., Wolfe, R. S., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.075 · Cited by 112
2023 China Guidelines for Lipid Management
Li, J., Zhao, S., Zhao, D., Lü, G., Peng, D., Liu, J., Chen, Z., Guo, Y., Wu, N., Yan, S.-K., et al. (2023) · 老年心脏病学杂志：英文版 · doi:10.26599/1671-5411.2023.09.008 · Cited by 120
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s010 · Cited by 107
Vascular cognitive impairment and dementia: Mechanisms, treatment, and future directions
Mok, V., Cai, Y., & Markus, H. S. (2024) · International Journal of Stroke · doi:10.1177/17474930241279888 · Cited by 120
Wong, N. D., Toth, P. P., & Amsterdam, E. A. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.11.013 · Cited by 105
PCSK9 Inhibition: From Current Advances to Evolving Future
Liu, C., Chen, J., Chen, H., Zhang, T., He, D., Luo, Q., Chi, J., Hong, Z., Liao, Y., Zhang, S., et al. (2022) · Cells · doi:10.3390/cells11192972 · Cited by 108
The PCSK9 revolution: Current status, controversies, and future directions
Warden, B. A., Fazio, S., & Shapiro, M. D. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.05.007 · Cited by 103
A new dawn for managing dyslipidemias: The era of rna-based therapies
Macchi, C., Sirtori, C. R., Corsini, A., Santos, R. D., Watts, G. F., & Ruscica, M. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104413 · Cited by 95
Cognition After Lowering LDL-Cholesterol With Evolocumab
Gencer, B., Mach, F., Guo, J., Im, K., Ruzza, A., Wang, H., Kurtz, C. E., Pedersen, T. R., KEECH, A. C., Ott, B. R., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.039 · Cited by 94
Self-citationO’Connell, E. M., & Lohoff, F. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00609 · Cited by 93
Goldstein, L. B., Toth, P. P., Dearborn, J. L., Giugliano, R. P., Hirsh, B. J., Peña, J. M., Selim, M. H., & Woo, D. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atv.0000000000000164 · Cited by 99
Self-citationToth, P. P., & Banach, M. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-23 · Cited by 99
Adverse Events Associated With PCSK 9 Inhibitors: A Real‐World Experience
Gürgöze, M. T., Muller-Hansma, A. H. G., Schreuder, M. M., Galema‐Boers, A. M. H., Boersma, E. H., & van Lennep, J. E. R. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1193 · Cited by 92
Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies
Seidah, N. G., Prat, A., Pirillo, A., Catapano, A. L., & Norata, G. D. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz003 · Cited by 91
Low levels of low-density lipoprotein cholesterol and cognitive decline
Hua, R., Ma, Y., Li, C., Zhong, B., & Xie, W. (2021) · 中国科学通报：英文版 · doi:10.1016/j.scib.2021.02.018 · Cited by 88
Penson, P. E., Long, D. L., Howard, G., Toth, P. P., Muntner, P., Howard, V. J., Safford, M. M., Jones, S. R., Martin, S. S., Mazidi, M., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy533 · Cited by 89
PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
Katzmann, J. L., Gouni‐Berthold, I., & Laufs, U. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.595819 · Cited by 91
Gragnano, F., & Calabrò, P. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.01.012 · Cited by 89
Harvey, P. D., Sabbagh, M. N., Harrison, J., Ginsberg, H. N., Chapman, M. J., Manvelian, G. Z., Moryusef, A., Mandel, J., & Farnier, M. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx661 · Cited by 89
Dyslipidemia Management in Adults With Diabetes
Lazarte, J., & Hegele, R. A. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.07.003 · Cited by 88
PCSK9 inhibitors for treating hypercholesterolemia
Pasta, A., Cremonini, A. L., Pisciotta, L., Buscaglia, A., Porto, I., Barra, F., Ferrero, S., Brunelli, C., & Rosa, G. M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1702970 · Cited by 88
How Low to Go With Glucose, Cholesterol, and Blood Pressure in Primary Prevention of CVD
Hong, K. N., Fuster, V., Rosenson, R. S., Rosendorff, C., & Bhatt, D. L. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.001 · Cited by 87
Underberg, J. A., Toth, P. P., & Rodríguez, F. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2117498 · Cited by 81
Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients
Strandberg, T. E. (2019) · Current Atherosclerosis Reports · doi:10.1007/s11883-019-0793-7 · Cited by 81
Small molecules as inhibitors of PCSK9: Current status and future challenges
Xu, S., Luo, S., Zhu, Z., & Xu, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.11.011 · Cited by 85
Macchi, C., Banach, M., Corsini, A., Sirtori, C., Ferri, N., & Ruscica, M. (2019) · European Journal of Preventive Cardiology · doi:10.1177/2047487319831500 · Cited by 78
Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
Preiss, D., Tobert, J. A., Hovingh, G. K., & Reith, C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.072 · Cited by 75
Lipids and peripheral neuropathy
Iqbal, Z., Bashir, B., Ferdousi, M., Kalteniece, A., Alam, U., Malik, R. A., & Soran, H. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000770 · Cited by 76
Masana, L., Girona, J., Ibarretxe, D., Rodríguez‐Calvo, R., Rosales, R., Vallvé, J.-C., Rodríguez-Borjabad, C., Guardiola, M., Rodríguez, M. M., Guaita‐Esteruelas, S., et al. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.12.018 · Cited by 71
Drexel, H., Coats, A. J. S., Spoletini, I., Bilato, C., Mollace, V., Filardi, P. P., & Rosano, G. M. C. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz079 · Cited by 71
Wilkinson, M. J., Lepor, N. E., & Michos, E. D. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028892 · Cited by 70
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 70
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Bardolia, C., Amin, N. S., & Turgeon, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789931 · Cited by 69
Adorni, M. P., Ruscica, M., Ferri, N., Bernini, F., & Zimetti, F. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00120 · Cited by 67
Khan, S. U., Talluri, S., Riaz, H., Rahman, H., Nasir, F., Bin Riaz, I., Sattur, S., Ahmed, H., Kaluski, E., & Krasuski, R. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318766612 · Cited by 61
Cesaro, A., Bianconi, V., Gragnano, F., Moscarella, E., Fimiani, F., Monda, E., Scudiero, O., Limongelli, G., Pirro, M., & Calabrò, P. (2020) · BioFactors · doi:10.1002/biof.1619 · Cited by 68
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
Claessen, B. E. P. M., Guedeney, P., Gibson, C. M., Angiolillo, D. J., Cao, D., Lepor, N. E., & Mehran, R. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018897 · Cited by 67
Thrombolysis In Myocardial Infarction (TIMI) Study Group
Sabatine, M. S., & Braunwald, E. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.01.060 · Cited by 70
Self-citationTan, D., Zhang, Z., Shi, H., Sun, N., Li, Q., Bi, S., Huang, J., Liu, Y., Guo, Q., & Jiang, C. (2024) · Advanced Materials · doi:10.1002/adma.202407751 · Cited by 64
Guedeney, P., Sorrentino, S., Giustino, G., Chapelle, C., Laporte, S., Claessen, B. E. P. M., Ollier, É., Camaj, A., Kalkman, D. N., Vogel, B., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa024 · Cited by 66
Nishikido, T., & Ray, K. K. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00199 · Cited by 65
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Lorenzatti, A. J., & Toth, P. P. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.06 · Cited by 62
New Pharmacological Approaches to Target PCSK9
Catapano, A. L., Pirillo, A., & Norata, G. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00847-7 · Cited by 63
Rosenson, R. S., Hegele, R. A., & Köenig, W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313238 · Cited by 61
Gragnano, F., Natale, F., Concilio, C., Fimiani, F., Cesaro, A., Sperlongano, S., Crisci, M., Limongelli, G., Calabrò, R., Russo, M. G., et al. (2017) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000611 · Cited by 60
Rao, A. S., Lindholm, D., Rivas, M. A., Knowles, J. W., Montgomery, S. B., & Ingelsson, E. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/circgen.118.002162 · Cited by 60
Picard, C., Poirier, A., Bélanger, S., Labonté, A., Auld, D., Poirier, J., & on behalf of the PREVENT-AD Research Group (2019) · PLOS ONE · doi:10.1371/journal.pone.0220254 · Cited by 59
Hovingh, G. K., Raal, F. J., Dent, R. E., Stefanutti, C., Descamps, O. S., Masana, L., Lira, A., Bridges, I. M., Coll, B., & SULLIVAN, D. R. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.09.003 · Cited by 61
Grześk, G., Dorota, B., Wołowiec, Ł., Wołowiec, A., Osiak, J., Kozakiewicz, M., & Banach, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113957 · Cited by 64
Hypercholesterolaemia – practical information for non-specialists
Soran, H., Adam, S., Mohamad, J. B., Ho, J. H., Schofield, J. D., Kwok, S., Siahmansur, T. J., Liu, Y., Syed, A. A., Dhage, S. S., et al. (2018) · Archives of Medical Science · doi:10.5114/aoms.2018.72238 · Cited by 59
Contemporary Management of Dyslipidemia
Ferraro, R., Leucker, T. M., Martin, S. S., Banach, M., Jones, S. R., & Toth, P. P. (2022) · Drugs · doi:10.1007/s40265-022-01691-6 · Cited by 59
Banach, M., & Penson, P. E. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy301 · Cited by 54
Management of Familial Hypercholesterolemia: Current Status and Future Perspectives
Lui, D. T. W., Lee, A. C. H., & Tan, K. C. B. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa122 · Cited by 63
PCSK9 acts as a key regulator of Aβ clearance across the blood–brain barrier
Mazura, A. D., Ohler, A., Storck, S. E., Kurtyka, M., Scharfenberg, F., Weggen, S., Becker-Pauly, C., & Pietrzik, C. U. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04237-x · Cited by 53
Malnutrition affects cholesterol paradox in coronary artery disease: a 41,229 Chinese cohort study
Wang, B., Liu, J., Chen, S., Ying, M., Chen, G., Liu, L., Lun, Z., Li, H., Huang, H., Li, Q., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01460-6 · Cited by 53
Macchi, C., Favero, C., Ceresa, A., Vigna, L., Conti, D. M., Pesatori, A. C., Racagni, G., Corsini, A., Ferri, N., Sirtori, C. R., et al. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01158-6 · Cited by 51
PCSK9 inhibitors and reduction in cardiovascular events: Current evidence and future perspectives
Nicholls, S. J. (2023) · Kardiologia Polska · doi:10.33963/kp.a2023.0030 · Cited by 58
Metadata
- Authors
- Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., Sabatine, M. S., Sever, P. S., Robinson, J. G., Honarpour, N., Wasserman, S. M., & Ott, B. R.
- Affiliations
- Oslo University Hospital (NO)
- University of Iowa (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-17
- Volume
- 377
- Issue
- 7
- Pages
- 633-643
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2746224452
- Cited by
- 492
- References
- 29
- Citations by year
- 2026: 36 · 2025: 39 · 2024: 35 · 2023: 41 · 2022: 46 · 2021: 63 · 2020: 68 · 2019: 63 · 2018: 75 · 2017: 23
- FWCI
- 64.10
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, other-oa)
- Spiral (Imperial College London) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10059)
- University of California, Davis
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- evolocumab, PCSK9 inhibitors, cognitive function, executive function, spatial working memory, working memory, episodic memory, psychomotor speed, LDL cholesterol, statin therapy, non-inferiority, cognitive safety, hypercholesterolemia, Alzheimer's disease risk, dementia risk, cognitive decline
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Anticholesteremic Agents, Cognition, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Cholesterol, LDL, Male, Memory, Middle Aged, Prospective Studies, Psychological Tests, Self-Assessment, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Atherosclerosis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
